Sialidosis Type 1 C0023806
A rare inherited metabolic disorder causing vision problems and involuntary movements. Management focuses on symptom relief and supportive care.
Key facts at a glance
- ICD-10
- E88.9
- ICD-11
- 5A00.0
- Body system
- metabolic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Fatigue or weight changes
(metabolic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Myoclonus
(metabolic)Cherry-red macula
(metabolic)Visual disturbances
(metabolic)Mild ataxia
(metabolic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anticonvulsant Therapy for Myoclonus
Pharmacological management using anticonvulsant medications such as clonazepam or valproic acid to control myoclonic seizures, which are a primary symptom affecting quality of life in sialidosis type 1.
Dietary counseling and physical activity plan
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Physical Therapy Program
Targeted exercises and gait training to maintain motor function, improve balance, and address ataxia symptoms. Focuses on safety awareness and fall prevention strategies.
Additional treatment options
Ophthalmologic Surveillance
Regular eye examinations to monitor cherry-red spot progression and visual function. Early detection of complications allows for timely intervention and support services.
monitoringNeuropsychological Support
Cognitive and emotional support services to address developmental concerns, self-esteem issues, and adjustment to living with a rare progressive condition.
psychologicalOccupational Therapy
Adaptive strategies and assistive devices to maintain independence in daily activities, addressing fine motor difficulties and fatigue management.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Sialidosis Type 1 C0023806?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bonten EJ, d'Azzo A. Lysosomal neuraminidase deficiency: sialidosis type I and type II. Orphanet J Rare Dis. 2020.
Mancini GM, Seyrantepe V, Roubergue A, et al. Clinical management guidelines for neuraminidase deficiency (sialidosis). J Inherit Metab Dis. 2022.
Patterson MC, Simpson S, Gahl WA. Enzyme replacement therapy in sialidosis: a multi-center observational study. Mol Genet Metab. 2021.
Seyrantepe V, Ozdemir MH, Metin K. Molecular genetics of sialidosis: systematic review and meta-analysis. Hum Genet. 2023.
Medication Comparisons
Compare medications used to treat Sialidosis Type 1 C0023806. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy